HUP0401665A1 - Egy aminotiazolil-acetanilid-származék alfa- és béta-kristályalakja, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények - Google Patents
Egy aminotiazolil-acetanilid-származék alfa- és béta-kristályalakja, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0401665A1 HUP0401665A1 HU0401665A HUP0401665A HUP0401665A1 HU P0401665 A1 HUP0401665 A1 HU P0401665A1 HU 0401665 A HU0401665 A HU 0401665A HU P0401665 A HUP0401665 A HU P0401665A HU P0401665 A1 HUP0401665 A1 HU P0401665A1
- Authority
- HU
- Hungary
- Prior art keywords
- aminothiazolyl
- alfa
- beta
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 5
- FJZCVRBXEZZTBP-UHFFFAOYSA-N 2-amino-n-phenyl-2-(1,3-thiazol-2-yl)acetamide Chemical class N=1C=CSC=1C(N)C(=O)NC1=CC=CC=C1 FJZCVRBXEZZTBP-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
%-5> A találmány tárgyát képezi az (R)-2-(2-amino-tiazol-4-il)-4'-[2-[(2-hidroxi-2-fenil-etil)-amino]-etil]-acetanilid a- és b-kristályalakja, és hatóanyagként való alkalmazásuk diabétesz ellenigyógyszer előállítására. Az a-kristályalak nem mutat higroszkóposságotés stabil, így alkalmazható gyógyszerként és felhasználható az iparitermelés tömegszintézisére. A b-kristályalak viszonylag kishigroszkóposságot mutat és szintén felhasználható az a-kristályalakelőállítási intermediereként. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001332914 | 2001-10-30 | ||
JP2001-332914 | 2001-10-30 | ||
PCT/JP2002/011217 WO2003037881A1 (fr) | 2001-10-30 | 2002-10-29 | Cristal a forme $g(a) ou $g(b) d'un derive acetanilinide |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0401665A1 true HUP0401665A1 (hu) | 2004-11-29 |
HUP0401665A3 HUP0401665A3 (en) | 2008-05-28 |
HU230481B1 HU230481B1 (hu) | 2016-07-28 |
Family
ID=19148268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401665A HU230481B1 (hu) | 2001-10-30 | 2002-10-29 | Egy acetanilid-származék alfa kristályalakja |
Country Status (17)
Country | Link |
---|---|
US (2) | US7342117B2 (hu) |
EP (3) | EP2298752B1 (hu) |
JP (1) | JP3800220B2 (hu) |
KR (1) | KR100908796B1 (hu) |
CN (1) | CN1243740C (hu) |
AU (1) | AU2002344419C1 (hu) |
BR (1) | BRPI0213570B8 (hu) |
CA (1) | CA2464068C (hu) |
ES (1) | ES2404071T3 (hu) |
HU (1) | HU230481B1 (hu) |
MX (1) | MXPA04003936A (hu) |
NO (1) | NO326965B1 (hu) |
PL (1) | PL218982B1 (hu) |
RU (1) | RU2303033C2 (hu) |
TW (1) | TW200300020A (hu) |
WO (1) | WO2003037881A1 (hu) |
ZA (1) | ZA200403044B (hu) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7342117B2 (en) * | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
MXPA05004925A (es) | 2002-11-07 | 2005-08-18 | Yamanouchi Pharma Co Ltd | Remedio para vejiga hiperactiva que incluye derivado de anilida de acido acetico como el ingrediente activo. |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
EP2527360B1 (en) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
DK2216021T3 (da) * | 2007-11-02 | 2012-11-05 | Astellas Pharma Inc | Farmaceutisk sammensætning til behandling af overaktiv blære |
TWI478712B (zh) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8586760B2 (en) | 2009-06-15 | 2013-11-19 | Auspex Pharmaceuticals, Inc. | Aminothiazole modulators of beta-3-adrenoreceptor |
JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
PT2554168T (pt) * | 2010-03-29 | 2018-02-28 | Astellas Pharma Inc | Composição farmacêutica de libertação controlada |
CA2802483C (en) * | 2010-06-16 | 2017-10-24 | Takeda Pharmaceutical Company Limited | Crystal of amide compound |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
KR101668514B1 (ko) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
US9655885B2 (en) | 2011-05-18 | 2017-05-23 | Dr. Reddy's Laboratories Ltd. | Amorphous mirabegron and processes for crystal forms of mirabegron |
EP2709993A4 (en) * | 2011-05-18 | 2015-02-25 | Reddys Lab Ltd Dr | AMORPHIC MIRABEGRON AND METHOD FOR CRYSTALLINE FORMS OF MIRABEGRON |
EP2832730A4 (en) | 2012-03-30 | 2015-09-09 | Astellas Pharma Inc | MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION |
CN103387500A (zh) * | 2012-05-11 | 2013-11-13 | 上海医药工业研究院 | 一种米拉贝隆及其中间体的制备方法 |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
SG11201501415RA (en) | 2012-08-31 | 2015-05-28 | Astellas Pharma Inc | Orally administered medical composition |
CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
WO2014132270A2 (en) * | 2013-02-27 | 2014-09-04 | Msn Laboratories Limited | Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CN103193730A (zh) * | 2013-04-17 | 2013-07-10 | 苏州永健生物医药有限公司 | 一种米拉贝隆的合成方法 |
CN103232368B (zh) * | 2013-04-18 | 2015-08-12 | 苏州永健生物医药有限公司 | 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法 |
CN103232352B (zh) * | 2013-05-11 | 2015-12-23 | 苏州永健生物医药有限公司 | (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯 |
EA201592263A1 (ru) | 2013-06-05 | 2016-05-31 | Синерджи Фармасьютикалз, Инк. | Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования |
WO2015040605A1 (en) | 2013-09-23 | 2015-03-26 | Ranbaxy Laboratories Limited | Crystalline form of mirabegron |
WO2015040573A1 (en) | 2013-09-23 | 2015-03-26 | Ranbaxy Laboratories Limited | Mirabegron dimethyl sulphoxide solvate and its use for the treatment of overactive bladder |
WO2015044965A1 (en) | 2013-09-30 | 2015-04-02 | Megafine Pharma (P) Ltd. | A process for preparation of mirabegron and alpha crystalline form thereof |
ITMI20131653A1 (it) | 2013-10-07 | 2015-04-08 | Dipharma Francis Srl | Forme cristalline di un agonista adrenergico |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN103641792B (zh) * | 2013-12-27 | 2015-07-22 | 国药集团国瑞药业有限公司 | 一种米拉贝隆有关物质或其盐、其制备方法和用途 |
CN104876889B (zh) * | 2014-02-27 | 2017-02-22 | 人福医药集团股份公司 | 化合物的合成方法 |
WO2015155664A1 (en) * | 2014-04-08 | 2015-10-15 | Suven Life Sciences Limited | An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide |
CN103896872A (zh) * | 2014-04-29 | 2014-07-02 | 黑龙江大学 | 米拉贝隆的合成方法 |
CN104016943A (zh) * | 2014-05-23 | 2014-09-03 | 苏州凯瑞医药科技有限公司 | 一种米拉贝隆的合成方法 |
CN104016877B (zh) * | 2014-06-13 | 2017-02-15 | 南京海融制药有限公司 | 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用 |
US9815771B2 (en) | 2014-08-06 | 2017-11-14 | Interquim, S.A. | Method for the synthesis of mirabegron and its derivatives |
WO2016024284A2 (en) | 2014-08-07 | 2016-02-18 | Wanbury Ltd. | A process for the preparation of mirabegron and its intermediates |
CN105481705A (zh) * | 2014-08-23 | 2016-04-13 | 南京海纳医药科技有限公司 | (r)-2-[[2-(4-氨基苯基)乙基]氨基]-1-苯乙醇的制备及应用 |
CN104230840A (zh) * | 2014-09-05 | 2014-12-24 | 安徽联创药物化学有限公司 | 米拉贝隆的合成方法 |
EP3197449B1 (en) | 2014-09-26 | 2018-11-21 | Universita' Degli Studi di Bari | Selective agonists of beta-adrenergic type 3 receptors (bar3) for the treatment of nephrogenic diabetes insipidus |
WO2016049749A1 (en) * | 2014-10-01 | 2016-04-07 | Apotex Inc. | Solid forms of mirabegron |
EP3253741A1 (en) | 2015-02-02 | 2017-12-13 | Lupin Limited | Process for preparation of polymorphic form of mirabegron |
JP2018090490A (ja) | 2015-03-31 | 2018-06-14 | アステラス製薬株式会社 | ミラベグロン含有医薬組成物 |
FR3043555B1 (fr) | 2015-11-17 | 2019-10-25 | Centre National De La Recherche Scientifique (Cnrs) | Mirabegron pour le traitement de maladies retiniennes |
EP3184516A1 (en) | 2015-12-23 | 2017-06-28 | Enantia, S.L. | Crystalline inclusion complexes of mirabegron with beta-cyclodextrin |
CN105801438A (zh) * | 2016-04-12 | 2016-07-27 | 济南大学 | 一种米拉贝隆中间体的合成方法 |
CN107963976A (zh) * | 2016-10-20 | 2018-04-27 | 中国动物疫病预防控制中心 | 一种苯乙醇胺类化合物中间体的制备方法 |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
SI3360866T1 (sl) | 2017-02-14 | 2019-04-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Mirabegronska predzdravila |
KR101868438B1 (ko) | 2017-04-13 | 2018-06-20 | (주) 성운파마코피아 | 아미드 유도체의 제조방법 |
KR102398639B1 (ko) | 2017-06-20 | 2022-05-17 | (주) 성운파마코피아 | 아미드 유도체의 염 및 그 제조방법 |
CN108658797A (zh) * | 2018-06-19 | 2018-10-16 | 安徽德信佳生物医药有限公司 | 一种米拉贝隆中间体(r)-2-(4-硝基苯乙基氨基)-1-苯基乙醇盐酸盐的合成 |
CN108947853A (zh) * | 2018-06-29 | 2018-12-07 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成米拉贝隆中间体的方法 |
KR101928987B1 (ko) * | 2018-08-28 | 2018-12-13 | (주) 성운파마코피아 | 신규한 고순도 미라베그론의 결정질 일수화물, 이의 제조방법 또는 용도 |
KR20200117091A (ko) | 2019-04-02 | 2020-10-14 | 제이투에이치바이오텍 (주) | 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도 |
CN110590699B (zh) * | 2019-09-29 | 2022-11-15 | 广东先强药业有限公司 | 一种米拉贝隆的精制方法 |
EP3722285B1 (en) | 2020-04-08 | 2022-03-30 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Process for preparing mirabegron enacarbil |
CN113816864B (zh) * | 2020-06-18 | 2024-03-29 | 南京正大天晴制药有限公司 | 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法 |
CN114539084B (zh) * | 2020-11-24 | 2024-04-02 | 威智医药股份有限公司 | 米拉贝隆及其中间体的制备方法 |
CN114539182B (zh) * | 2020-11-24 | 2024-08-09 | 威智医药股份有限公司 | 转晶溶剂及其应用和米拉贝隆α晶型的制备方法 |
KR20220081033A (ko) | 2020-12-08 | 2022-06-15 | 주식회사 한서켐 | 미라베그론 α형 결정의 제조방법 |
CN112574137A (zh) * | 2021-01-19 | 2021-03-30 | 南京美瑞制药有限公司 | 一种α晶型米拉贝隆的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1921577B2 (de) * | 1969-04-28 | 1972-04-06 | Nixdorf Computer Ag, 4790 Paderborn | Trommelartige vorrichtung zn buchungs- und schreibautomaten mit greifeinrichtung zum erfassen und einziehen von kontokarten o dgl |
JPH02279685A (ja) | 1989-04-18 | 1990-11-15 | Yoshitomi Pharmaceut Ind Ltd | 新規な結晶構造を有するチアジアジン化合物およびその製造法 |
CA2305802C (en) * | 1997-10-17 | 2008-11-18 | Yamanouchi Pharmaceutical Co., Ltd. | Amide derivatives or salts thereof |
JP3901832B2 (ja) | 1998-03-13 | 2007-04-04 | 大日本インキ化学工業株式会社 | キノリノン誘導体製剤、及びその製造法 |
JP2000212168A (ja) | 1999-01-22 | 2000-08-02 | Yamanouchi Pharmaceut Co Ltd | ヘキサヒドロ―1,4―ジアゼピン誘導体塩水和物の新規結晶 |
AU754138B2 (en) * | 1999-09-10 | 2002-11-07 | Mariposa Health Limited | Quinolinone derivative preparations and process for producing the same |
US6706733B2 (en) * | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
US7342117B2 (en) * | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
-
2002
- 2002-10-20 US US10/494,018 patent/US7342117B2/en not_active Expired - Lifetime
- 2002-10-28 TW TW091132011A patent/TW200300020A/zh not_active IP Right Cessation
- 2002-10-29 WO PCT/JP2002/011217 patent/WO2003037881A1/ja active Application Filing
- 2002-10-29 BR BRPI0213570A patent/BRPI0213570B8/pt active IP Right Grant
- 2002-10-29 EP EP10075435A patent/EP2298752B1/en not_active Expired - Lifetime
- 2002-10-29 HU HU0401665A patent/HU230481B1/hu unknown
- 2002-10-29 AU AU2002344419A patent/AU2002344419C1/en active Active
- 2002-10-29 EP EP08004921A patent/EP1932838A3/en not_active Withdrawn
- 2002-10-29 ES ES10075435T patent/ES2404071T3/es not_active Expired - Lifetime
- 2002-10-29 JP JP2003540162A patent/JP3800220B2/ja not_active Expired - Lifetime
- 2002-10-29 CN CNB02821370XA patent/CN1243740C/zh not_active Expired - Lifetime
- 2002-10-29 MX MXPA04003936A patent/MXPA04003936A/es active IP Right Grant
- 2002-10-29 CA CA002464068A patent/CA2464068C/en not_active Expired - Lifetime
- 2002-10-29 PL PL369874A patent/PL218982B1/pl unknown
- 2002-10-29 EP EP02779929A patent/EP1440969A4/en not_active Withdrawn
- 2002-10-29 KR KR1020047006428A patent/KR100908796B1/ko active IP Right Review Request
- 2002-10-29 RU RU2004116313/04A patent/RU2303033C2/ru active
-
2004
- 2004-04-21 ZA ZA2004/03044A patent/ZA200403044B/en unknown
- 2004-05-28 NO NO20042227A patent/NO326965B1/no not_active IP Right Cessation
-
2008
- 2008-01-14 US US12/007,653 patent/US7982049B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0401665A1 (hu) | Egy aminotiazolil-acetanilid-származék alfa- és béta-kristályalakja, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0400240A2 (hu) | Szubsztituált oxazolidinonszármazékok és más hatóanyagok kombinációi és ezeket tartalmazó gyógyszerkészítmények | |
ES2133504T3 (es) | Derivados peptidicos del acido boronico con una actividad inhibidora de proteasa, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
CY1107703T1 (el) | Υποκατεστημενες δικετοπιπεραζινες και χρηση αυτων ως ανταγωνιστες οξυτοκινης | |
DK0766696T3 (da) | Thiazolidinderivater, fremstilling af disse forbindelser og lægemidler indeholdende disse forbindelser | |
HUP0401504A2 (hu) | Antidiabetikumként és kóros elhízás elleni szerekként alkalmazható szubsztituált azol-karbonsavszármazékok és az ezeket tartalmazó gyógyszerkészítmények | |
SE0101038D0 (sv) | Novel compounds | |
HUP0401092A2 (hu) | 6-Fenil-7-[(fluor-alkil)-amino]-5-halogén-triazolopirimidinek mint fungicidek, előállításuk és alkalmazásuk | |
HUP0104033A2 (hu) | Benzoilpiridazin-származékok, a vegyületeket tartalmazó gyógyszerkészítmények, eljárás az előállításukra és alkalmazásuk | |
HUP0203884A2 (hu) | Kristályos oximinoalkánsav-származékok és cukorbaj elleni alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
IT1300055B1 (it) | Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici | |
HUP0401318A2 (hu) | 2,3,4,5-Tetrahidro-benzo[b] tiepin-1,1-dioxid-származékokat és további hatóanyagokat tartalmazó kombinációs készítmények és ezek alkalmazása | |
CY1109545T1 (el) | Συνθεση της (r) και (s)-αμινοκαρνιτινης και παραγωγων που προκυπτουν απο to d- και l- ασπαρτικο οξυ | |
WO2001060822A8 (fr) | Derives d'aminoacides et leur utilisation en tant qu'inhibiteurs de la nep, l'ace et l'ece | |
HUP0300651A2 (hu) | Nátrium-hidrogén-cserélő 1-es típusú inhibitor (NHE-1) alkalmazása gyógyszerkészítmények előállítására és ezt tartalmazó gyógyszerkészítmények | |
HUP0402553A2 (hu) | Venlafaxin-hidroklorid-monohidrát, eljárások előállítására, az ezt tartalmazó gyógyszerkészítmények és alkalmazásuk | |
PE9296A1 (es) | Forma polimorfica cristalina de (s,s,s)- n- (1-[ 2- carboxi- 3-(n�- mesil- lisilamino) propil]- 1-ciclopentil carbonil )tirosina (forma o) y procesos de obtencion | |
HUP0003710A2 (hu) | 2-[3-{4-[2-terc-Butil-6-(trifluor-metil)-4-pirimidinil]-1-piperazinil}-propil-tio]-4-pirimidinol-fumarát, valamint ezt a vegyületet tartalmazó gyógyászati készítmény | |
EP0666253A4 (en) | ANALOG OF N-t-BUTYLANILINE AND REDUCER OF THE LIPID RATE CONTAINING IT. | |
ATE298564T1 (de) | Arzneimittelformulierung enthaltend einen ltb4 antagonisten und einen netzmittel | |
IT1300056B1 (it) | Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci | |
UA48032A1 (uk) | ГІДРОХЛОРИД <font face="Symbol">b</font>-ДІЕТИЛАМІНОЕТИЛАМІДУ 6-МЕТОКСИБЕНЗОТІАЗОЛІЛ-2-ОКСАМІНОВОЇ КИСЛОТИ, ЯКИЙ ПРОЯВЛЯЄ АНТИАЛЕРГІЙНУ, АНАЛГЕТИЧНУ ТА ЖАРОЗНИЖУЮЧУ АКТИВНІСТЬ | |
HUP0301199A2 (hu) | Dioxo-tiazolidin-származék és antidiabetikumként történő alkalmazása | |
UA48057A1 (uk) | 5-АЛКІЛ-2-(1,3,4-ТІАДІАЗОЛІЛ)АМІДИ-<font face="Symbol">a</font>-МЕТИЛ-<font face="Symbol">d</font>-ДІЕТИЛАМІНОБУТИЛАМІДУ БУРШТИНОВОЇ КИСЛОТИ, ЯКІ МАЮТЬ ПРОТИЗАПАЛЬНУ АКТИВНІСТЬ | |
HUP0203476A2 (en) | Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate, use thereof and pharmaceutical composition containing the same |